America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the key benefits of AOH1996 compared to traditional chemotherapy treatments?
**Interview with Dr. Linda Malkas on the Breakthrough in Targeted Chemotherapy**
**Interviewer:** Thank you for joining us today, Dr. Malkas. You’ve been a significant part of a groundbreaking development in cancer treatment. Can you tell us about this new drug, AOH1996?
**Dr. Linda Malkas:** Thank you for having me. AOH1996 is a novel molecule designed to specifically target cancer cells by focusing on a protein known as PCNA, which plays a crucial role in DNA replication and tumor growth. Our approach acts like a ‘blizzard’ that can effectively shut down the metabolic hubs within cancer cells without disrupting normal cells.
**Interviewer:** That sounds innovative! How has the drug performed in your tests so far?
**Dr. Linda Malkas:** In our recent study published in the journal ‘Cell Chemical Biology,’ we tested AOH1996 on over 70 different cancer cell lines, and the results were very encouraging. The molecule selectively induced cell death in cancer cells by disrupting their normal reproductive cycle, while sparing healthy cells.
**Interviewer:** It seems like this drug has the potential to treat various types of cancer. Can you elaborate on that?
**Dr. Linda Malkas:** Absolutely. AOH1996 has shown efficacy in treating several cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. This broad spectrum allows us to explore its use for multiple cancer types, which is quite promising.
**Interviewer:** What are the next steps for AOH1996 in terms of development and testing?
**Dr. Linda Malkas:** The next crucial step involves advancing our findings into clinical trials with human participants. This will help us understand the drug’s effectiveness and safety in a real-world setting.
**Interviewer:** Lastly, how do you envision the impact of this drug on cancer treatment in the future?
**Dr. Linda Malkas:** I believe AOH1996 could revolutionize the way we approach cancer therapy, offering a more targeted and less toxic option for patients. If successful, it may become a key component of cancer treatment regimens, helping to improve survival rates and the quality of life for countless individuals battling this disease.
**Interviewer:** Thank you, Dr. Malkas, for sharing this exciting advancement with us. We look forward to seeing how AOH1996 progresses in the coming years.
**Dr. Linda Malkas:** Thank you for having me. I’m excited about the future of cancer treatment!
